Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007

ion of the purchase price to the assets acquired and liabilities assumed, based on their fair values.

Book Value Fair Value Fair Value



____________ ___________ ___________

Non-current assets:

Other intangible assets, net

- Intellectual property -

developed technology - 1,133.3 1,133.3

- Favourable manufacturing

contracts - 9.2 9.2

- In process research and

development - 1,943.3 1,943.3

Property, plant and equipment, net 2.6 (1.8) 0.8

Deferred tax assets, non-current 1.1 52.4 53.5

Current assets:

Inventories 4.8 6.6 11.4

Accounts receivable, net 0.3 - 0.3

Prepaid expenses and other

current assets 2.4 (2.2) 0.2

Purchased call option 141.8 - 141.8

Short-term investments 55.8 - 55.8

Cash and cash equivalents 74.9 - 74.9

Non-current liabilities:

Sold warrants (133.0) 133.0 -

Deferred income, non-current (59.5) 59.5 -

Deferred tax liability,

non-current (1.1) (1,109.5) (1,110.6)

Current liabilities:

Convertible loan notes (279.4) - (279.4)

Accounts payable and accrued

expenses (33.3) 1.6 (31.7)<

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Henderson, CA (PRWEB) July 30, 2014 ... hosting presentations of leading Immunologists, Principle Investigators, scientists ... Charles J Malemud, Professor at Case Western ... be delivering his keynote address on “The ... TNF-a in production of matrix metalloproteinase-9”. Arya Biragyn, ...
(Date:7/29/2014)... July 29, 2014 The advanced optical ... brain that are driving a revolution in the neurosciences ... peer-reviewed journal published by SPIE, the international society ... coincides with the launch of the BRAIN Initiative in ... that lay out a vision for and provide examples ...
(Date:7/29/2014)... A team of researchers has created a new ... three-dimensional textures. These surfaces, made by self-assembly of ... properties including controllable mechanical stiffness and strength, ... certain direction. , "We have demonstrated that mechanical ... form complex three-dimensional microstructures, and that we can ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4A new way to make microstructured surfaces 2
... Korea, August 8, 2011Can a flexible LED conformably placed on ... human brain, or rolled upon the blood vessels, diagnose or ... in the near future. The team of Professor Keon ... developed a new concept: a biocompatible, flexible Gallium Nitride (GaN) ...
... (OTCBB: IAGX) announced today that it received an adverse ... its pending dispute with former distributor TriPharma, LLC and ... a private arbitrator and is conducted under the rules ... Diego, California.  The interim award against the Company and ...
... Sept. 19, 2011 announces that ... in its catalogue: Established ... There ... focused clusters of biotechnology companies and related ...
Cached Biology Technology:Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
(Date:7/30/2014)... University Professor Steven Chown has been awarded the ... for Excellence in Antarctic Research. , SCAR, an ... high quality international scientific research in the Antarctic ... region in the Earth system. The organisation also ... Treaty System, responsible for governing the region. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... Mitochondrial diseases disrupt the power generating machinery within cells ... in the lungs or respiratory tract. A new study ... shows that infection with the pneumonia causing bacteria ... a signaling protein that is associated with mitochondrial disease. ...
... Stony Brook, N.Y., July 27, 2009 - Temperature ... amphibians, crustaceans, and lizards live longer at higher latitudes ... week in the Proceedings of the National Academy ... Dr. Stephan Munch and Ph.D. candidate Santiago Salinas, both ...
... Los Angeles, London, New Delhi, Singapore and Washington DC ... special issue of Medical Decision Making , a ... overwhelm hospital resources even with an extremely effective public ... the attack and initiating a response to it. ...
Cached Biology News:Stress signals link pre-existing sickness with susceptibility to bacterial infection 2Warmer environment means shorter lives for cold-blooded animals 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
Biology Products: